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The management of T2DM requires aggressive treatment to achieve glycemic and cardiovascular risk factor goals.
In this setting, metformin, an old and widely accepted first line agent, stands out not only for its antihyperglycemic
properties but also for its effects beyond glycemic control such as improvements in endothelial dysfunction,
hemostasis and oxidative stress, insulin resistance, lipid profiles, and fat redistribution. These properties may have
contributed to the decrease of adverse cardiovascular outcomes otherwise not attributable to metformin’s mere
antihyperglycemic effects. Several other classes of oral antidiabetic agents have been recently launched, introducing
the need to evaluate the role of metformin as initial therapy and in combination with these newer drugs. There is
increasing evidence from in vivo and in vitro studies supporting its anti-proliferative role in cancer and possibly a
neuroprotective effect. Metformin’s negligible risk of hypoglycemia in monotherapy and few drug interactions of
clinical relevance give this drug a high safety profile. The tolerability of metformin may be improved by using an
appropiate dose titration, starting with low doses, so that side-effects can be minimized or by switching to an
extended release form. We reviewed the role of metformin in the treatment of patients with type 2 diabetes and
describe the additional benefits beyond its glycemic effect. We also discuss its potential role for a variety of insulin
resistant and pre-diabetic states, obesity, metabolic abnormalities associated with HIV disease, gestational diabetes,
cancer, and neuroprotection.
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The discovery of metformin began with the synthesis of
galegine-like compounds derived from Gallega officinalis,
a plant traditionally employed in Europe as a drug for dia-
betes treatment for centuries [1]. In 1950, Stern et al.
discovered the clinical usefulness of metformin while
working in Paris. They observed that the dose–response
of metformin was related to its glucose lowering capacity
and that metformin toxicity also displayed a wide security
margin [1].
Metformin acts primarily at the liver by reducing glu-
cose output and, secondarily, by augmenting glucose up-
take in the peripheral tissues, chiefly muscle. These
effects are mediated by the activation of an upstream
kinase, liver kinase B1 (LKB-1), which in turn regulates
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distribution, and reproduction in any mediumco-activator, transducer of regulated CREB protein 2
(TORC2), resulting in its inactivation which conse-
quently downregulates transcriptional events that pro-
mote synthesis of gluconeogenic enzymes [2]. Inhibition
of mitochondrial respiration has also been proposed to
contribute to the reduction of gluconeogenesis since it
reduces the energy supply required for this process [3].
Metformin’s efficacy, security profile, benefic cardio-
vascular and metabolic effects, and its capacity to be
associated with other antidiabetic agents makes this drug
the first glucose lowering agent of choice when treating
patients with type 2 diabetes mellitus (TDM2).Metformin and pre-diabetes
In 2000, an estimated 171 million people in the world
had diabetes, and the numbers are projected to double
by 2030. Interventions to prevent type 2 diabetes, there-
fore, have an important role in future health policies.
Developing countries are expected to shoulder the ma-
jority of the burden of diabetes [4]. One of the mainntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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style which promotes obesity and sedentarism [5].
Impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG) statuses are associated with increased and
varying risk of developing type 2 diabetes mellitus. IGT
has been associated with an increased risk of cardiovas-
cular events and may determine an increased mortality
risk. The association of IFG with cardiovascular events,
however, has not been well established [6].
When lifestyle interventions fail or are not feasible,
pharmacological therapy may be an important resource
to prevent type 2 diabetes. Several different drug classes
have been studied for this purpose.
In their systematic review, Gillies et al. found that life-
style and pharmacological interventions reduced the rate
of progression to type 2 diabetes in people with IGT and
that these interventions seem to be as effective as pharma-
cological treatment. Although compliance was high, treat-
ment effect was not sustained after treatment was
stopped. According to the results of their meta-analysis,
lifestyle interventions may be more important in those
with higher mean baseline body mass index BMI [5].
The best evidence for a potential role for metformin in
the prevention of type 2 diabetes comes from The Dia-
betes Prevention Program (DPP) trial. Lifestyle interven-
tion and metformin reduced diabetes incidence by 58%
and 31%, respectively, when compared with placebo [7].
At the end of the DPP study, patients were observed for
a one to two week wash out period. Diabetes incidence
increased from 25.2 to 30.6% in the metformin group and
from 33.4 to 36.7% in the placebo group. Even after in-
cluding the wash out period in the overall analysis,
metformin still significantly decreased diabetes incidence
(risk ratio 0.75, p = 0.005) compared with placebo [8].
These data suggest that, at least in the short-term,
metformin may help delay the onset of diabetes. The
benefits of metformin were primarily observed in patients
<60 years old (RR 0.66) and in patients with a BMI greater
than 35 kg/m2 (RR 0.47) [7] (Table 1).
Metformin significantly reduced the risk of developing
diabetes in an Indian population of subjects with IGT.
The relative risk reduction was 28.5% with lifestyle
modification (p = 0.018), 26.4% with metformin (p =Table 1 Effectiveness of metformin in diabetes prevention of
Study Randomized Country N
DPP [7] yes USA 3234
IDPP [9] yes India 522
Yang et al. [10] yes China 321
DPPOS [11] yes USA 2766
DPP: Diabetes Prevention Program, DPP: Indian Diabetes Prevention Program, DPPO
Lifestyle modification.0.029), and 28.2% with lifestyle modification plus
metformin (p = 0.022), as compared with the control
group [9] (Table 1).
In a Chinese study, subjects with IGT randomly
assigned to receive either low-dose metformin (750 mg/
day) or acarbose (150 mg/day) in addition to lifestyle
intervention were compared to a control group that only
received life style intervention. Treatment with metformin
or acarbose produced large, significant, and similar risk
reductions for new onset of T2DM of 77% and 88%, re-
spectively; these reductions were larger than that of life-
style intervention alone [10].
The persistence of the long-term effects obtained
through DPP interventions were evaluated at an add-
itional follow-up after a median of 5.7 years. Individuals
were divided in 3 groups: lifestyle, metformin, and
placebo. Diabetes incidence rates were similar between
treatment groups: 5.9 per 100 person-years (5.1–6.8) for
lifestyle, 4.9 (4.2–5.7) for metformin, and 5.6 (4.8–6.5)
for placebo. Diabetes incidence 10 years since DPP
randomization was reduced by 34% and 18% in the life-
style and metformin group, respectively [11] (Table 1).
The prevalence of pre-diabetes as well as the progression
rate to diabetes may differ between different populations,
making the application of results from certain studies of dif-
ferent ethnical groups inappropriate. IGT is highly prevalent
in native Asian Indians. This population has several unique
features such as a young age of diabetes onset and lower
BMI along with high rates of insulin resistance and lower
thresholds for diabetic risk factors [12]. Chinese individuals
have a lower prevalence of diabetes and are less insulin re-
sistant than Indians, so the results of the Chinese study may
not be applicable to Asian Indian individuals [13].
In a meta-analysis of randomized controlled trials,
Salpeter et al. reported a reduction of 40% in the inci-
dence of new-onset diabetes with an absolute risk reduc-
tion of 6% (95% CI, 4–8) during a mean trial duration of
1.8 years [14].
Lily and Godwin reported a decreased rate of conver-
sion from pre-diabetes to diabetes in individuals with
IGT or IFG in their systematic review and meta-analysis
of randomized controlled trials. This effect was seen at
both a higher metformin dosage (850 mg twice daily)patients with impaired glucose tolerance
Duration
years
Mean change in risk
MET (%)
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daily) in people of varied ethnicity [15].
Metformin in the management of adult diabetic patients
Current guidelines from the American Diabetes Associ-
ation/European Association for the Study of Diabetes
(ADA/EASD) and the American Association of Clinical
Endocrinologists/American College of Endocrinology
(AACE/ACE) recommend early initiation of metformin
as a first-line drug for monotherapy and combination
therapy for patients with T2DM. This recommendation
is based primarily on metformin’s glucose-lowering
effects, relatively low cost, and generally low level of side
effects, including the absence of weight gain [16,17].
Metformin’s first-line position was strengthened by the
United Kingdom Prospective Diabetes Study (UKPDS)
observation that the metformin-treated group had risk
reductions of 32% (p = 0.002) for any diabetes-related
endpoint, 42% for diabetes-related death (p = 0.017), and
36% for all-cause mortality (p = 0.011) compared with
the control group. The UKPDS demonstrated that
metformin is as effective as sulfonylurea in controlling
blood glucose levels of obese patients with type 2 dia-
betes mellitus [18]. Metformin has been also been shown
to be effective in normal weight patients [19].
Metformin in combination therapy
Although monotherapy with an oral hypoglycemic agent
is often initially effective, glycemic control deteriorates
in most patients which requires the addition of a second
agent. Currently, marketed oral therapies are associated
with high secondary failure rates [20]. Combinations of
metformin and insulin secretagogue can reduce HbA1c
between 1.5% to 2.2% in patients sub-optimally con-
trolled by diet and exercise [21].
The optimal second-line drug when metformin mono-
therapy fails is not clear. All noninsulin antidiabetic
drugs when added to maximal metformin therapy are
associated with similar HbA1c reduction but with
varying degrees of weight gain and hypoglycemia risk.
A meta-analysis of 27 randomized trials showed that
thiazolidinediones, sulfonylureas, and glinides were
associated with weight gain; glucagon-like peptide-1
analogs, glucosidase inhibitors, and dipeptidyl peptidase-4
inhibitors were associated with weight loss or no weight
change. Sulfonylureas and glinides were associated with
higher rates of hypoglycemia than with placebo. When
combined with metformin, sulfonylureas and alpha-
glucosidase inhibitors show a similar efficacy on HbA1c [22].
Metformin and sulfonylureas
The combination of metformin and sulfonylurea (SU) is
one of the most commonly used and can attain a greater
reduction in HbA1c (0.8–1.5%) than either drug alone[23,24]. The glimepiride/metformin combination results
in a lower HbA1c concentration and fewer hypoglycemic
events when compared to the glibenclamide/metformin
combination [25]. The use of metformin was associated
with reduced all-cause mortality and reduced cardiovas-
cular mortality. Metformin and sulfonylurea combin-
ation therapy was also associated with reduced all-cause
mortality [26].
Epidemiological investigations suggest that patients on
SUs have a higher cardiovascular disease event rate than
those on metformin. Patients who started SUs first and
added metformin also had higher rates of cardiovascular
disease events compared with those who started metformin
first and added SUs. These investigations are potentially
affected by unmeasured confounding variables [27].
Metformin and insulin
Metformin as added to insulin-based regimens has been
shown to improve glycemic control, limit changes in
body weight, reduce hypoglycemia incidence, and to re-
duce insulin requirements (sparing effect), allowing a
15–25% reduction in total insulin dosage [28,29].
The addition of metformin to insulin therapy in type 1
diabetes is also associated with reductions in insulin-
dose requirement and HbA1c levels [30,31].
Metformin and thiazolinediones
The addition of rosiglitazone to metformin in a 24-week
randomized, double-blind, parallel-group study signifi-
cantly decreased HbA1c concentration and improved insu-
lin sensitivity and HOMA ß cell function [32]. However, in
spite of preventing diabetes incidence, the natural course
of declining insulin resistance may not be modified by a
low dose of the metformin-rosiglitazone combination [33].
The ADOPT study (A Diabetes Outcome Progression
Trial) assessed the efficacy of rosiglitazone, as compared
to metformin or glibenclamide, in maintaining long-term
glycemic control in patients with recently diagnosed type
2 diabetes. Rosiglitazone was associated with more weight
gain, edema, and greater durability of glycemic control;
metformin was associated with a higher incidence of
gastrointestinal events and glibenclamide with a higher
risk of hypoglycaemia. [34].
Metformin and glifozins
Dapagliflozin, a highly selective inhibitor of SGLT2, has
demonstrated efficacy, alone or in combination with
metformin, in reducing hyperglycemia in patients with
type 2 diabetes [35,36]. Studies are in development for
assessing the safety and efficacy of this combination.
Metformin and α glicosidase inhibitor
Acarbose reduces the bioavailability of metformin [37].
However, it has been reported that the association of
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patients reduced HbA1c by about 0.8-1.0% [38].
Metformin and incretin-based therapies
DDPIV prolongs the duration of active glucagon-like
peptide 1 (GLP-1) by inhibiting DPPIV peptidase, an en-
zyme which cleaves the active form of the peptide. This
action results in an improvement of insulin secretion as
a physiological response to feeding. The mechanism of
DPPIV inhibitors is complementary to that of metformin
which improves insulin sensitivity and reduces hepatic
glucose production, making this combination very useful
for achieving adequate glycemic control [39]. Metformin
has also been found to increase plasma GLP-1 levels,
probably by either direct inhibition of DPPIV or by
increased secretion, leading to reduced food intake and
weight loss [40].
Saxagliptin added to metformin led to clinically and
statistically significant reductions in HbA1c from base-
line versus metformin/placebo in a 24-week randomized,
double-blind, placebo-controlled trial. Saxagliptin at
doses of 2.5, 5, and 10 mg plus metformin decreased A1
by 0.59%, 0.69%, and 0.58%, respectively, in comparison
to an increase in the metformin plus placebo group
(+0.13%); p < 0.0001 for all comparisons [41].
A meta-analysis of 21 studies examined incretin-based
therapy as an add-on to metformin in patients with T2DM
for 16–30 weeks; 7 studies used a short-acting GLP-1 re-
ceptor agonist (exenatide BID), 7 used longer acting GLP-1
receptor agonists (liraglutide or exenatide LAR), and 14
examined DPP-IV inhibitors. Long-acting GLP-1 receptor
agonists reduced HbA1c and fasting glucose levels to a
greater extent than the other therapies [42].
Metformin and pregnancy
Metformin is known to cross the placenta and concerns
regarding potential adverse effects on both the mother
and the fetus have limited its use in pregnancy [43]. The
use of metformin during pregnancy is still a matter of
controversy.
Two meta-analyses of observational studies, one of
women using metformin and/or sulfonylureas and one of
women using metformin alone during the first trimester,
did not show an increase in congenital malformations or
neonatal deaths [44,45].
The Metformin in Gestational Diabetes (MiG) trial,
found no significant difference in the composite fetal out-
come (composite of neonatal hypoglycemia, respiratory
distress, need for phototherapy, birth trauma, 5-minute
Apgar score <7, or prematurity) between metformin and
insulin. Women assigned to metformin had more preterm
births and less weight gain compared to those in the insu-
lin group [46]. Another randomized trial also found simi-
lar results [47].Results of the MiG TOFU reported that infants of dia-
betic mothers exposed to metformin in utero and
examined at 2 years of age may present a reduction in
insulin resistance, probably related to an increase in sub-
cutaneous fat [48].
Longer follow-up studies will be required to determine
metformin’s impact on the development of obesity and
metabolic syndrome in offspring.
Metformin use in childhood and adolescence
Type 2 diabetes mellitus has dramatically increased in
children and adolescents worldwide to the extent that
has been labeled an epidemic [49]. Before 1990, it was a
rare condition in the pediatric population; by 1999, the
incidence varied from 8% to 45%, depending on geo-
graphic location, and was disproportionally represented
among minority groups [50]. There are few studies of
metformin use in the pediatric population. Most of them
are of short duration and heterogeneous designs.
The beneficial role of metformin in young patients with
type 2 diabetes has been demonstrated in a randomized, con-
trolled trial which showed a significant decrease in fasting
blood glucose, HbA1c, weight, and total cholesterol. The
most frequently reported adverse events were abdominal
pain, diarrhea, nausea/vomiting, and headaches. There were
no cases of clinical hypoglycemia, lactic acidosis, or clinically
significant changes in physical examinations [51]. When
compared to glimepiride (1–8 mg once daily), metformin
(500–1000 mg twice daily) lowered HbA1c to <7%, similar
to glimepiride, but was associated with significantly less
weight gain. A total of 42.4% and 48.1% of subjects in the
glimepiride and metformin groups, respectively, in the
intent-to-treat population achieved A1C levels of <7.0% at
week 24 [52].
There is some evidence that suggests improvement in
metabolic control of poorly controlled adolescents with
type 1 diabetes when metformin is added to insulin ther-
apy. Metformin has been shown to reduce insulin dose
requirement (5.7–10.1 U/day), HbA1c (0.6–0.9%), weight
(1.7–6.0 kg), and total cholesterol (0.3–0.41 mmol/l)
[30]. A previous review showed similar results in HbA1
reduction and insulin requirement, however no
improvements in insulin sensitivity, body composition,
or serum lipids were documented [31].
Metformin indications for management of obesity, insulin
resistance, and non-alcoholic fatty liver in children and
adolescents
Insulin resistance in obese children and adolescents
should be appropriately and aggressively addressed once
it is linked to known cardiovascular risks such as IGT,
T2DM, dyslipidemia, and hypertension [53,54]. Non-
alcoholic fatty (NAFLD) disease, a frequent cause of
chronic liver disease in obese adults, is also associated
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sion to fibrosis and cirrhosis [55] with an increased rela-
tive risk of cardiovascular events or death [56]. The true
prevalence of NAFLD in children is underestimated. The
prevalence of steatosis in obese children was estimated
to be 38% in a large retrospective autopsy study [57].
Currently, the best supported therapy for NAFLD is
gradual weight loss through exercise and nutritional sup-
port [58]. Metformin is associated with short-term
weight loss, improvement of insulin sensitivity, and
decreased visceral fat [59]. A reduction in ALT, GGT,
and fatty liver incidence and severity has also been
described with metformin use [60].
Metformin has been used increasingly in obese chil-
dren with hyperinsulinemia although there are no strong
evidence-based studies supporting its use for this clinical
condition. A moderate improvement in body muscular
index (BMI) and insulin sensitivity has been reported
with the use of metformin [61,62]. Heart rate recovery
(HRR) may also improve due to improved parasympa-
thetic tone, paralleling improvements in BMI, insulin
levels, and insulin sensitivity [61]. HRR has been
considered a predictor of mortality and cardiovascular
disease in otherwise healthy subjects [63]. A poor HRR
has also been linked to insulin resistance [64] and to a
higher risk for developing T2DM [65].
Metformin may not be as effective as behavioral
interventions in reducing BMI and when compared with
drugs that are licensed for obesity, its effects are moder-
ate [66].
Effects of metformin on vascular protection
Effects on cardiovascular mortality
Diabetic patients are at high risk of cardiovascular
events, particularly of coronary heart disease by about
3-fold [67,68]. It has been stated that type 2 diabetic
patients without a previous history of myocardial infarc-
tion have the same risk of coronary artery disease (CAD)
as non-diabetic subjects with a history of myocardial in-
farction [69]. This has led the National Cholesterol Edu-
cation Program to consider diabetes as a coronary heart
disease risk equivalent [70]. Although there is no doubt
that there is an increased risk of CAD events in diabetic
patients, there is still some uncertainty as to whether the
cardiovascular risk conferred by diabetes is truly equiva-
lent to that of a previous myocardial infarction [71].
In 1980, Scambato et al. reported that, in a 3-year ob-
servational study of 310 patients with ischaemic cardio-
myopathy, patients treated with metformin had reduced
rates of re-infarction, occurrence of angina pectoris,
acute coronary events other than acute myocardial in-
farction, and death in patients [72]. The largest effect
was seen in re-infarction rates; a post hoc analysis
showed that this effect was significant (p = 0.003). Afterthis study, the UKPDS, the largest randomized clinical
trial in the newly-diagnosed type 2 diabetic population
largely free of prior major vascular events, randomly
assigned treatment with metformin to a subgroup of
overweight individuals (>120% of ideal body weight). In
1990, another subgroup of patients (n = 537), who were
receiving the maximum allowed dosage of sulfonylurea,
were randomized either to continue sulfonylurea therapy
or to allow an early addition of metformin [18].
Metformin provided greater protection against the de-
velopment of macrovascular complications than would
be expected from its effects upon glycemic control
alone. It had statistically significant reductions in the risk
of all-cause mortality, diabetes-related mortality (p =
0.017), and any end-point related to diabetes (p = 0.002),
but not in myocardial infarction (p = 0.052) [18]. The
UKPDS pos-trial reported significant and persistent risk
reductions for any diabetes-related end point (21%, p =
0.01), myocardial infarction (33%, p = 0.005), and death
from any cause (27%, p = 0.002) [73].
Following UKPDS, other studies have reported signifi-
cant improvement of all-cause mortality and cardiovascu-
lar mortality (Table 2). A retrospective analysis of patients
databases in Saskatchewan, Canada reported significant
reductions for all-cause mortality and cardiovascular mor-
tality of 40% and 36%, respectively [26]. The PRESTO trial
showed significant reductions of any clinical event (28%),
myocardial infarction (69%), and all-cause mortality (61%)
[74]. The HOME trial reported a decreased risk of
developing macrovascular disease [75]. In non-diabetic
subjects with normal coronary arteriography but also with
two consecutive positive (ST depression > 1 mm) exercise
tolerance test, an 8-week period on metformin improved
maximal ST-segment depression, Duke score, and chest
pain incidence compared with placebo [76]. A recent
meta-analysis suggested that the cardiovascular effects of
metformin could be smaller than had been hypothesized
on the basis of the UKPDS; however, its results must be
interpreted with caution given the low number of
randomized controlled trials included [77].
Metformin and heart failure
The risk of developing cardiac heart failure (CHF) in
diabetic individuals nearly doubles as the population
ages [77]. DM and hyperglycemia are strongly implicated
as a cause for the progression from asymptomatic left
ventricular dysfunction to symptomatic HF, increased
hospitalizations for HF, and an overall increased mortal-
ity risk in patients with chronic HF [78]. Despite all its
benefits, metformin is contraindicated in patients with
heart failure due to the potential risk of developing lactic
acidosis, a rare but potentially fatal metabolic condition
resulting from severe tissue hypoperfusion [79]. The US
Food and Drug Administration removed the heart failure
Table 2 Metformin effects on vasculoprotection
Study Design Duration Key findings
UKPDS 33 [18] Prospective 10 yr Significant reduction in all-cause mortality, diabetes related mortality, and any end-point related to
diabetes.
Sgambato et al. [72] Retrospective 3 yr Trend towards reduction in angina symptoms (p = 0.051). Significant lower re-infarction rates.
Johnson et al. [24] Retrospective 9 yr Reduction of all-cause mortality and of cardiovascular mortality
Kao et al. [74] Prospective 2 yr Significant risk reduction for any clinical event, myocardial infarction and all-cause mortality
Jadhav et al. [76] Prospective 8 weeks Improved maximal ST depression, Duke score, and chest pain incidence
Kooy et al. [75] Prospective 4, 3 yr Reduction of the risk of developing macrovascular disease
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though a strong warning for the cautious use of
metformin in this population still exists [80].
Several retrospective studies in patients with CHF and dia-
betes reported lower risk of death from any cause [81-83],
lower hospital readmissions for CHF [81], and hospitalizations
for any cause [81,82]. A recent review concluded that CHF
could not be considered an absolute contraindication for
metformin use and also suggest its protective effect in redu-
cing the incidence of CHF and mortality in T2DM [83]. This
protective effect may due to AMPK activation and decrease in
cardiac fibrosis [83].
In a prospective 4-year study, 393 metformin-treated
patients with elevated serum creatinine between 1.5–
2.5 mg/dL and coronary artery disease, CHF, or chronic
obstructive pulmonary disease (COPD) were randomized
into two groups. One group continued metformin ther-
apy while the other was instructed to discontinue
metformin. Patients with CHF had either New York
Heart Association (NYHA) Class III or Class IV CHF
and were receiving diuretic and vasodilatation drugs.
There were no differences between groups in all-cause
mortality, cardiovascular mortality, rate of myocardial
infarction, or rate of cardiovascular events [84].
Patients with DM and advanced, systolic HF (n = 401)
were divided into 2 groups based on the presence or ab-
sence of metformin therapy. The cohort had a mean age
of 56 ± 11 years and left ventricular ejection fraction
(LVEF) of 24 ± 7% with 42% and 45% being NYHA III
and NYHA IV, respectively. Twenty-five percent (n = 99)
were treated with metformin therapy. Metformin-treated
patients had a higher BMI, lower creatinine, and were
less often on insulin. One-year survival in metformin-
treated and non-metformin-treated patients was 91%
and 76%, respectively (p = 0.007). After a multivariate
adjustment for demographics, cardiac function, renal
function, and HF medications, metformin therapy was
associated with a non-significant trend of improved sur-
vival [85].
Many different mechanisms, beyond glycemic control,
have been implicated in vascular protection induced by
metformin such as improvements in the inflammatorypathway [86], coagulation [87], oxidative stress and
glycation [88-92], endothelial dysfunction [88-90], haemo-
stasis [88,91-93], insulin resistance improvement [94],
lipid profiles [95,96], and fat redistribution [97,98]. Some
of these mechanisms are described below.
Beyond glycemic control
The UKPDS recruited patients with newly diagnosed
type 2 diabetes and demonstrated that tight glycemic
control has beneficial effects on microvascular end
points. However, it failed to show improvements in
macrovascular outcomes. The improved cardiovascular
disease (CVD) risk in overweight diabetic patients
treated with metformin was attributed to its effects
extending beyond glycemic control [18].
Effects on the inflammatory pathway
The benefits of metformin on macrovascular complications
of diabetes, separate from its conventional hypoglycemic
effects, may be partially explained by actions beyond
glycemic control, particularly by actions associated with in-
flammatory and atherothrombotic processes [86]. Metformin
can act as an inhibitor of pro-inflammatory responses
through direct inhibition of NF-kB by blocking the PI3K–
Akt pathway. This effect may partially explain the apparent
clinical reduction of cardiovascular events not fully attribut-
able to metformin’s anti-hyperglycemic action [86].
Some studies also point to a modest effect on inflam-
matory markers in subjects with IGT in T2DM [87]
while others have found no effect at all [88].
Effects on oxidative stress
Oxidative stress is believed to contribute to a wide range
of clinical conditions such as inflammation, ischaemia-
reperfusion injury, diabetes, atherosclerosis, neurodegen-
eration, and tumor formation [99].
Metformin has antioxidant properties which are not
fully characterized. It reduces reactive oxygen species
(ROS) by inhibiting mitochondrial respiration [100] and
decreases advanced glycosylation end product (AGE) in-
directly through reduction of hyperglycemia and directly
through an insulin-dependent mechanism [101].
Rojas and Gomes Diabetology & Metabolic Syndrome 2013, 5:6 Page 7 of 15
http://www.dmsjournal.com/content/5/1/6There is some evidence that metformin also has a
beneficial effect on some components of the antioxidant
defense system. It can upregulate uncoupled proteins 2
(UCP2) in adipose tissue [102] and can also cause an in-
crease in reduced glutathione [100].
Metformin has been proposed to cause a mild and transi-
ent inhibition of mitochondrial complex I which decreases
ATP levels and activates AMPK-dependent catabolic
pathways [100], increasing lipolysis and ß-oxidation in white
adipose tissue [102] and reducing neoglucogenesis [2]. The
resultant reduction in triglycerides and glucose levels could
decrease metylglyoxal (MG) production through lipoxidation
and glycoxidation, respectively [99,101].
Recently a study described a putative mechanism relat-
ing metformin action and inhibition of oxidative stress,
inflammatory, and proapoptotic markers [103]. In this
study, treatment of bovine capillary endothelial cells
incubated in hyperglycemic medium with metformin
was able to decrease the activity of NF-kB and others
intracellular proteins related to cellular metabolic mem-
ory. The authors suggested that this action could be
mediated by histone deacetylase sirtuin 1 (SIRT-1), a
multifunctional protein involved in many intracellular
pathways related to metabolism, stress response, cell
cycle, and aging [103].
Effects on endothelial function
Type 2 diabetes is associated with a progressive and
generalized impairment of endothelial function that affects
the regulation of vasomotor tone, leucocyte adhesion,
hemostasis, and fibrinolysis. These effects are probably
direct and not related to decreases in hyperglycemia [88].
Contradictory effects of metformin on endothelial
function have been described, however [89,90]. Mather
et al. reported that metformin has no effect on endothe-
lium dependent blood flow but has a significant effect
on endothelium independent blood flow and insulin re-
sistance reduction [89]. Conversely, Vitale et al. found
significant improvement of endothelium dependent flow
without a significant effect on endothelium independent
response [90]. Further studies are necessary to establish
the effect of metformin on endothelial function.
Effects on body weight
Metformin may have a neutral effect on body weight of
patients with T2DM when compared to diet [18] or may
limit or decrease the weight gain experienced with
sulfonylureas [18], TDZ [104], insulin [29,75], HAART
[97], and antipsychotics drugs [94].
Modest weight loss with metformin has been observed
in subjects with IGT [15,18]. However, a meta-analysis
of overweight and obese non-diabetic subjects, found no
significant weight loss as either a primary or as second-
ary outcome [105].The mechanisms by which metformin contributes to
weight loss may be explained through the reduction in
gastrointestinal absorption of carbohydrates and insulin
resistance [95], reduction of leptin [95] and ghrelin levels
after glucose overload [96], and by induction of a
lipolitic and anoretic effect by acting on glucagon–like
peptide 1 [40].
Effects on lipid profile
Metformin is associated with improvements in lipopro-
tein metabolism, including decreases in LDL-C [95],
fasting and postprandial TGs, and free fatty acids [106].
Effects on blood pressure
The hypertension associated with diabetes has an unclear
pathogenesis that may involve insulin resistance. Insulin
resistance is related to hypertension in both diabetic and
non-diabetic individuals and may contribute to hyperten-
sion by increasing sympathetic activity, peripheral vascular
resistance, renal sodium retention [107], and vascular
smooth muscle tone and proliferation [108,109].
Data of the effects of metformin on BP are variable,
with neutral effects or small decreases in SBP and DBP
[110]. In the BIGPRO1 trial carried out in upper-body
obese non-diabetic subjects with no cardiovascular
diseases or contraindications to metformin, blood pres-
sure decreased significantly more in the IFG/IGT sub-
group treated with metformin compared to the placebo
group (p < 0.03) [111].
Effects on thyroid function
Metformin decreases serum levels of thyrotropin (TSH)
to subnormal levels in hypothyroid patients that use
levothyroxin (LT4) on a regular basis [112]. A significant
decrease in TSH (P < 0.001) without reciprocal changes
in any thyroid function parameter in diabetic patients
had also been reported but only in hypothyroid subjects,
not in euthyroid ones [113].
The mechanism of the drop in TSH is unclear at this
time. Some of the proposed explanations for this effect
are enhanced inhibitory modulation of thyroid hormones
on central TSH secretion, improved thyroid reserve in
patients with hypothyroidism [113], changes in the affin-
ity or the number of thyroid hormone receptors,
increased dopaminergic tone, or induced constituent ac-
tivation of the TSH receptor [112].
Metformin and HIV lypodystrofy
Antiretroviral therapy has been associated with an
increased prevalence of type 2 diabetes mellitus and in-
sulin resistance among HIV-infected patients [114].
Lipodystrophy, characterized by morphological (periph-
eral lipoatrophy, localized fat accumulation) and meta-
bolic changes (hyperlipidemia, insulin resistance and
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active antiretroviral therapy (HAART), occurring in 40%
to 80% of patients [115].
Nucleoside reverse transcriptase inhibitors (NRTIs), par-
ticularly thymidine analogues (zidovudine and stavudine),
have been associated with morphological changes, particu-
larly extremity fat loss [116], while protease inhibitors
(PIs) have been associated with biochemical derangements
of glucose and lipids as well as with localized accumula-
tion of fat [117].
Lifestyle modifications such as diet and exercise and
switching antiretroviral therapies seems to be of limited
value in reducing visceral abdominal fat (VAT). Metformin
has been shown to reduce VAT [97,98] but at the expense
of accelerating peripheral fat loss [118]. Favorable effects on
insulin levels [98], insulin sensitivity [119], weight [97],
flow-mediated vasodilation [119], and lipid profiles [98,119]
have also been described.Effects on hemostasis
Therapeutic doses of metformin in type 2 diabetic
patients lower circulating levels of several coagulation
factors such as plasminogen activator inhibitor (PAI-1),
von Williebrand Factor (vWF), tissue type plasminogen
activator [88], factor VII [91]. It has also direct effects
on fibrin structure and function by decreasing factor
XIII activity and changing fibrin structure [92].
Furthermore, plasma levels of PAI-1 and vWF, which
are secreted mainly by the impaired endothelium, have
been shown to decrease with metformin therapy in non-
diabetic subjects [93].Metformin and neuroprotection
Alzheimer’s disease (AD), one of the most common
neurodegenerative diseases, has been termed type 3 dia-
betes. It is a brain specific form of diabetes characterized
by impaired insulin actions and neuronal insulin resist-
ance [120] that leads to excessive generation and accu-
mulation of amyloid oligomers, a key factor in the
development of AD [121].
The mechanisms of cerebral metabolism are still un-
clear. A network of different factors is most likely re-
sponsible for its maintenance. The activated protein
kinase (AMPK) forms a molecular hub for cellular meta-
bolic control [122]. Recent studies of neuronal models
are pointing to possible AMPK roles beyond energy
sensing with some reporting protective effects [123]
while others report detrimental effects, particularly
under extreme energy depletion [124].
AMPK is activated in the brain by metabolic stresses
that inhibit ATP production such as ischemia, hypoxia,
glucose deprivation, metabolic inhibitors (metformin), as
well as catabolic and ATP consuming processes [122].The human brain is characterized by an elevated oxida-
tive metabolism and low antioxidants enzymes, which
increases the brain’s vulnerability to oxidative stress [125].
Oxidative stress has been implicated in a variety of neuro-
logical diseases, including Alzheimer’s disease, Parkinson’s
disease, and amyotrophic lateral sclerosis disease [126].
Mitochondrial dysfunction has a pivotal role in oxidative
stress. In this setting, the permeability transition pore
(PTP) acts as a regulator of the apoptotic cascade under
stress conditions, triggering the release of apoptotic
proteins and subsequent cell death [127]. It was reported
that metformin prevents PTP opening and subsequent cell
death in various endothelial cell types exposed to high glu-
cose levels [128]. Metformin could interrupt the apoptotic
cascade in a model of ectoposide-induced cell death by
inhibiting PTP opening and blocking the release of
cytochrome-c. These events together with other factors
from the mitochondrial intermembrane space are critical
processes in the apoptotic cascade [125].
Insulin has been shown to regulate a wide range of
processes in the central nervous system such as food in-
take, energy homeostasis, reproduction, sympathetic ac-
tivity, learning and memory [129], as well as neuronal
proliferation, apoptosis, and synaptic transmission [130].
With regard to ß amyloid, a report has shown that
metformin increases ß amyloid in cells through an
AMPK-dependent mechanism, independent of insulin sig-
naling and glucose metabolism. This effect is mediated by
a transcriptional upregulation of ß secretase (BACE 1)
which leads to an increase of ß amyloid [131]. However,
when insulin is added to metformin, it potentiates insulin’s
effects on amyloid reduction, improves neuronal insulin
resistance, and impairs glucose uptake and AD-associated
neuropathological characteristics by activating the insulin
signaling pathway [129].
Metformin has been shown to promote rodent and
human neurogenesis in culture by activating a protein kin-
ase C-CREB binding protein (PKC-CBP) pathway, recruiting
neural stem cells and enhancing neural function, particularly
spatial memory function. It is noteworthy that neural stem
cells can be recruited in an attempt of endogeneously
repairing the injured or regenerating brain [132]. In the con-
text of metformin’s potential neuroprotective effect in vivo,
the capacity of the drug to cross the blood brain barrier
needs to be further elucidated. Provided that this crossing
could occur, metformin may become a therapeutic agent
not only in peripheral and diabetes-associated vascular neur-
opathy but also in neurodegenerative diseases.
Metformin and cancer
Patients with type 2 diabetes have increased risks of various
types of cancer, particularly liver, pancreas, endometrium,
colon, rectum, breast, and bladder cancer. Cancer mortality
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cidence of different types of cancer in patients as well a
reduced cancer-related mortality in patients using metformin
(Table 3).
The underlying mechanisms of tumorigenesis in T2DM
seem to be related to insulin resistance, hyperinsulinemia,
elevated levels of IGF-1 [140-142], and hyperglycemia with
the latter driving ATP production in cancer cells through
the glycolytic pathway, a mechanism known as the
Warburg effect [142].
Metformin significantly reduces tumorigenesis and
cancer cell growth although how it does it is not well
understood. It may be due to its effects on insulin reduc-
tion and hyperinsulinemia, and consequently on IGF-1
levels, which have mitogenic actions enhancing cellular
proliferation,but may also involve specific AMPK-
mediated pathways [133].
Activation of AMPK leads to inhibition of mTOR
through phosphorylaton and subsequent activation of
the tumor suppressor tuberous sclerosis complex 2
(TSC2). The mTOR is a key integrator of growth factor
and nutrient signals as well as a critical mediator of the
PI3K/PKB/Akt pathway, one of the most frequently
disregulated signaling pathways in human cancer [144].
Metformin may have additional anticancer properties in-
dependent of AMPK, liver kinase 1 (LKB1), and TSC2.
This may be related, in part, to the inhibition of Rag
GTPase-mediated activation of mTOR [145].
Patients with type 2 diabetes who are prescribed
metformin had a lower risk of cancer compared to patients
who did not take it. The reduced risk of cancer and cancer
mortality observed in these studies has been consistently in
the range of 25% to 30% [135-139,145-147]. An observa-
tional cohort study with type 2 diabetics who were new
metformin users found a significant decrease in cancer inci-
dence among metformin users (7.3%) compared to controls
(11.6%). The unadjusted hazard ratio (95% CI) for cancer
was 0.46 (0.40–0.53). The authors suggested a dose-relatedTable 3 Reduced incidence and cancer-related mortality in m
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*Confounding adjustment: Adjustment of variables that could potentially interfere wresponse [136]. In an observational study of women with
type 2 diabetes, a decreased risk of breast cancer among
metformin users was only seen with long-term use [137].
Metformin use is associated with lower cancer-related
mortality. A prospective study (median follow-up time of
9.6 years) found that metformin use at baseline was
associated with lower cancer-related mortality and that this
association appeared to be dose dependent [138]. Diabetic
patients with colorectal cancer who were treated with
metformin had lower mortality than those not receiving
metformin [139]. Patients with type 2 diabetes exposed to
sulfonylureas and exogenous insulin had a significantly
increased risk of cancer-related mortality compared with
patients exposed to metformin. However, whether this
increased risk is related to a deleterious effect of
sulfonylurea and insulin or a protective effect of metformin
or due to some unmeasured effect related to both choice
of therapy and cancer risk is not known [147].
The proposed mechanisms of metformin anti-cancer
properties are not fully understood. Most are mainly
mediated through AMPK activation which requires LKB1,
a well-known tumor suppressor [2]. Some of these
mechanisms may be through inhibition of cell growth
[148], IGF-1 signaling [149], inhibition of the mTOR path-
way [150], reduction of human epidermal growth factor
receptor type 2 (HER-2) expression (a major driver of
proliferation in breast cancer) [151], inhibition of angio-
genesis and inflammation [152], induction of apoptosis
and protein 53 (p53) activation [153], cell cycle arrest
[137,154], and enhancement of cluster of differenciation 8
(CD8) T cell memory [155].
Future roles for metformin in cancer therapy
In vitro and in vivo studies strongly suggest that
metformin may be a valuable adjuvant in cancer treat-
ment. Some of the proposed future roles yet to be




IMC, smoking, blood pressure, material deprivation
Age, BMI, smoking, estrogen use, diabetes history, HbA1c, renal
failure, congestive heart failure, ischemic heart disease
Sex, age, smoking, DM-2, duration of diabetes, HbA1c, insulin
use, oral antidiabetic medication, IMC, risk factors
Sex, age, BMI, alcohol abuse, HBV and HCV infection, DM-2, ALT
level
Sex, age, BMI, HbA1c, deprivation
Other drug use
ith cancer incidence.
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When compared to those on other treatments,
metformin users had a lower risk of cancer. A dose-
relationship has been reported [138,144,145].
Adjunct in chemotherapy
Type 2 diabetic patients receiving neo-adjuvant
chemotherapy for breast cancer as well as metformin
were more likely to have pathologic complete response
(pCR) than patients not receiving it. However, despite the
increase in pCR, metformin did not significantly improve
the estimated 3-year relapse-free survival rate [156].
Tumor relapse prevention
Cancer stem cells may be resistant to
chemotherapeutic drugs, therefore regenerating the
various tumor cell types and promoting disease relapse.
Low doses of metformin inhibited cellular
transformation and selectively killed cancer stem cells
in four genetically different types of breast cancer in a
mouse xenograft model. The association of metformin
and doxorubicin killed both cancer stem cells and non-
stem cancer cells in culture. This may reduce tumor
mass and prevent relapse more effectively than either
drug used as monotherapy [157].
Metformin contraindications
Metformin is contraindicated in patients with diabetic
ketoacidosis or diabetic precoma, renal failure or renal
dysfunction, and acute conditions which have the poten-
tial for altering renal function such as: dehydration, se-
vere infection, shock or intravascular administration of
iodinated contrast agents, acute or chronic disease
which may cause tissue hypoxia (cardiac or respiratory
failure, recent myocardial infarction or shock), hepatic
insufficiency, and acute alcohol intoxication in the case
of alcoholism and in lactating women [158]. Several
reports in literature related an increased risk of lactic
acidosis with biguanides, mostly phenformin, with an
event rate of 40–64 per 100,000 patients years [159]
whereas the reported incidence with metformin is 6.3
per 100,000 patients years [160].
Structural and pharmacokinetic differences in metformin
such as poor adherence to the mitochondrial membrane,
lack of interference with lactate turnover, unchanged excre-
tion, and inhibition of electron transport and glucose oxida-
tion may account for such differences [161].
Despite the use of metformin in cases where it is
contraindicated, the incidence of lactic acidosis has not
increased. Most patients with case reports relating
metformin to lactic acidosis had at least one or more
predisposing conditions for lactic acidosis [161].
Renal dysfunction is the most common risk factor
associated with lactic acidosis but so far there is no clear
evidence indicating at which level of renal dysfunction
metformin should be discontinued or contraindicated inorder to prevent lactic acidosis. Some authors have
suggested discontinuing its use when serum creatinine is
above 1.5 mg/dL in men and 1.4 mg/dL in women [103]
while others suggested a cut-off of 2.2 mg/dL and continu-
ous use even in the case of ischaemic cardiopathy, chronic
obstructive pulmonary disease, or cardiac failure [84].
As serum creatinine can underestimate renal dysfunc-
tion, particularly in elderly patients and women, the use
of estimated GFR (eGFR) has been advocated. The
recommended eGFR thresholds are generally consistent
with the National Institute for Health and Clinical Excel-
lence guidelines in the U.K. and those endorsed by the
Canadian Diabetes Association and the Australian Dia-
betes Society. Metformin may be continued or initiated
with an eGFR of 60 mL/min per 1.73 m2 but renal func-
tion should be monitored closely (every 3–6 months).
The dose of metformin should be reviewed and reduced
(e.g. by 50% or to half-maximal dose) in those with an
eGFR of 45 mL/min per 1.73 m2, and renal function
should be monitored closely (every 3 months). Metformin
should not be initiated in patients at this eGFR [162]. The
drug should be stopped once eGFR falls to 30 mL/min per
1.73 m2. Frid et al. supports these recommendations
through findings that above 30 ml/min/1.73 m2 metformin
levels rarely goes above 20 mmol/l, which seems to be a
safe level [163].
Another clinical condition associated with lactic acid-
osis in patients using metformin is heart failure [79].Adverse effects
Gastrointestinal intolerance occurs quite frequently in
the form of abdominal pain, flatulence, and diarrhea
[164]. Most of these effects are transient and subside
once the dose is reduced or when administered with
meals. However, as much as 5% of patients do not toler-
ate even the lowest dose [165].
About 10–30% of patients who are prescribed metformin
have evidence of reduced vitamin B12 absorption due to
calcium-dependent ileal membrane antagonism, an effect
that can be reversed with supplemental calcium [166]. This
vitamin B12 deficiency is rarely associated with megalo-
blastic anemia [167].
A multicentric study reported a mean decrease of 19%
and 5% in vitamin B12 and folate concentration, respect-
ively [168]. Vitamin B12 deficiency has been related with
dose and duration of metformin use and occurs more
frequently among patients that use it for more than 3 -
years and in higher doses [169].
Other adverse reactions are sporadic, such as
leucocytoclastic vasculitis, allergic pneumonitis [170],
cholestatic jaundice [171], and hemolytic anaemia [172].
Hypoglycemia is very uncommon with metformin
monotherapy [173] but has been reported in combination
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therapeutic agents.
Drug interactions
Clinically significant drug interactions involving metformin
are rare. Some cationic agents such as amiloride, digoxin,
morphine, procainamide, quinidine, quinine, ranitidine,
triamterene, trimethoprim, and vancomycin that are
eliminated by renal tubular secretion may compete with
metformin for elimination. Concomitant administration of
cimetidine, furosemide, or nifedipine may also increase the
concentration of metformin. Patients receiving metformin
in association with these agents should be monitored for
potential toxicity. Metformin should be discontinued at
least 48 hours prior to the administration of iodinated con-
trast media which can produce acute renal failure and
should only be restarted if renal function is normal [175].
Tolerability
Gastrointestinal side-effects are common with the use of
metformin of standard release and are usually associated
with rapid titration and high-dose initiation of metformin.
These effects are generally transient, arise early in the
course of treatment, and tend to subside over time
[176]. The gastrointestinal side-effects can be addressed
by taking the agent with meals, reducing the rate of dose
escalation, or transferring to a prolonged-release formu-
lation [177].
Some studies point to a dose-related relationship of
the incidence of side-effects [178] whereas other evi-
dence gives no support for a dose-related effect of
metformin on the gastrointestinal system [179].
Metformin XR
The metformin XR formulation releases the active drug
through hydrated polymers which expand after uptake
of fluid, prolonging gastric residence time which leads to
slower drug absorption in the upper gastrointestinal
tract and allows once-daily administration [180].
A prospective open label study assessed metformin XR ef-
fectiveness on three cardiovascular risk factors: blood glucose
(HbA1c, fasting blood glucose, and postprandial blood glu-
cose); total cholesterol, LDL cholesterol, HDL cholesterol;
and triglycerides and blood pressure. No significant
differences were observed by any anthropometric, clinical, or
laboratory measures except for plasma triglycerides which
were lower in the group switched to metformin XR [181].
Metformin tolerability as well as patient acceptance was
greater in the group switched to metformin XR. Other stud-
ies have found good to excellent glycemic control with
metformin XR in type 2 diabetic patients who did not have
well-controlled diet and exercise alone [182]. Metformin XR
has been associated with improved tolerability [182] and
increased compliance [183].Conclusions
In recent years, metformin has become the first-line ther-
apy for patients with type 2 diabetes. Thus far, metformin is
the only antidiabetic agent which has shown reduced
macrovascular outcomes which is likely explained by its
effects beyond glycemic control. It has also been employed
as an adjunct to lifestyle modifications in pre-diabetes and
insulin-resistant states. A large amount of evidence in lit-
erature supports its use even in cases where it would be
contra-indicated mainly due to the fear of lactic acidosis
which has been over-emphasized as the available data sug-
gest that lactate levels and risk of lactic acidosis do not
differ appreciably in patients taking this drug versus other
glucose-lowering agents. It has also recently gained atten-
tion as a potential treatment for neurodegenerative diseases
such as Alzheimer’s disease.
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